Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Cereno Scientific.

    Client Virtual Booth

    CERENO SCIENTIFIC

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Cereno Scientific
    Sweden Flag
    Country
    Country
    Sweden
    Address
    Address
    BioVentureHub Pepparedsleden 1 431 83 Mölndal, Sverige
    Telephone
    Telephone
    556890–4071
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://cerenoscientific.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/cereno-scientific-ab/?originalSubdomain=se
    Twitter
    Twitter
    https://twitter.com/cerenosciab

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Cereno Scientific Broadens Patent Protection for Drug Candidate CS585 and Strengthens Its Future Commercial Position in the US

    Details:

    Preclinical data from drug candidate CS585 demonstrating that it targets the IP receptor for prevention of thrombosis without increased risk of bleeding.


    Lead Product(s): CS585

    Therapeutic Area: Cardiology/Vascular Diseases Product Name: CS585

    Highest Development Status: PreclinicalProduct Type: Small molecule

    Partner/Sponsor/Collaborator: University of Michigan

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable September 09, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Cereno Scientific Obtains IND Acceptance from FDA to Start Phase II Study with Drug Candidate CS1 in PAH

    Details:

    CS1 is an HDAC (Histone DeACetylase) inhibitor that acts as an epigenetic modulator with anti-thrombotic, anti-inflammatory, anti-fibrotic and pressure-relieving properties, all relevant for PAH.


    Lead Product(s): CS1

    Therapeutic Area: Cardiology/Vascular Diseases Product Name: CS1

    Highest Development Status: Phase IProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable September 17, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    veranova-m-2024-04-22

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search